Gemigliptin tartrate is a highly selective, reversible, and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. It exhibits potent anti-glycation properties and can be used for the research of advanced glycation end products (AGE)-related diabetic complications. This product is for research use only.
- Highly selective, reversible, and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor
- IC50 of 10.3 nM for human recombinant DPP-4
- Exhibits potent anti-glycation properties
- Useful for research of advanced glycation end products (AGE)-related diabetic complications
- Dose-dependently inhibits the formation of AGE-BSA
- Suppresses the cross-linking of preformed AGE-BSA with rat tail tendon collagen
- Inhibits AGEs formation and AGE cross-links in vivo
- Dose-dependently inhibits plasma DPP-4 activity in various animal models